FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

gton, D.C. 20549	OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

1. Name and Address of Reporting Person*  Hatzis-Schoch Brent						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Black Diamond Therapeutics, Inc. [ BDTX ]									heck al ا ر	ationship of Repor all applicable) Director Officer (give title		ng Person(s) to Issue 10% Own Other (spe		wner
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/03/2020										below)  See Remarks					
(Street) CAMBRI (City)	IDGE M	Α (	)2142 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)						, 4 and Secu Bene		cially l Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount (A)		(A) or (D)	Price	Trans		saction(s) r. 3 and 4)			(111511.4)
Common Stock 02/03					02/03/2020				P		3,000	(1)	A	\$1	\$19		3,000		D	
		Та	able II - I )								sed of, onvertib				y Owr	ned				
1. Title of Derivative Security (Instr. 3)	erivative curity or Exercise nstr. 3)  Price of Derivative Security  Date (Month/Day/Year)  Price of Derivative Security  Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  8)		Transa Code ( 8)	ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date Expiration			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amount or Numbe of			ınt Der		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	, O F D 0 (!)	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

1. On February 3, 2020, Reporting Person purchased 3,000 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.

## Remarks:

Chief Operating Officer and General Counsel

/s/ Brent Hatzis-Schoch 02/05/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.